Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Day One Biopharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BRISBANE, CALIF., DEC. 16, 2025 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS, INC. (NASDAQ: DAWN) (DAY ONE OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED THAT DR. JEREMY BENDER, CHIEF EXECUTIVE OFFICER, WILL PRESENT DURING THE 44TH ANNUAL J.P.

DAY ONE TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

UPDATED DATA EXPANDS CLINICALLY MEANINGFUL RESULTS AVAILABLE FROM FIREFLY-1 PIVOTAL TRIAL 77% OF PATIENTS WHO ENTERED THE TREATMENT-FREE OBSERVATION PERIOD FOLLOWING OJEMDA TREATMENT REMAINED OFF THERAPY FOR AT LEAST 12 MONTHS THE MEDIAN TIME TO NEXT TREATMENT (TTNT) FOLLOWING INITIATION OF OJEMDA EXCEEDED 3.5 YEARS  BRISBANE, CALIF., NOV. 24, 2025 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS, INC. (NASDAQ: DAWN) (DAY ONE OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED THREE-YEAR RESULTS FROM THE OJEMDA PIVOTAL PHASE 2 FIREFLY-1 TRIAL IN AN ORAL PRESENTATION AT THE 30TH ANNUAL MEETING & EDUCATION DAY OF THE SOCIETY FOR NEURO-ONCOLOGY.

DAY ONE ANNOUNCES THREE YEAR FOLLOW-UP DATA FROM OJEMDA (TOVORAFENIB) PHASE 2 FIREFLY-1 TRIAL AT THE 2025 SOCIETY FOR NEURO-ONCOLOGY (SNO) ANNUAL MEETING

BRISBANE, CALIF., NOV. 18, 2025 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS, INC. (NASDAQ: DAWN) (DAY ONE OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE ON TUESDAY, DECEMBER 2, 2025 AT 4:00 P.M. EST.

DAY ONE TO PARTICIPATE IN THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

ACQUISITION EXPANDS DAY ONE'S PORTFOLIO WITH NOVEL ANTIBODY-DRUG CONJUGATE (ADC) EMILTATUG LEDADOTIN (EMI-LE) EMI-LE HAS DEMONSTRATED EARLY ANTI-TUMOR ACTIVITY IN AN ONGOING PHASE 1 STUDY FOR ADENOID CYSTIC CARCINOMA TYPE-1 (ACC-1), A CANCER WITH HIGH UNMET NEED AND A LACK OF THERAPEUTIC OPTIONS DAY ONE WILL APPLY EXISTING SCIENTIFIC AND COMMERCIAL CAPABILITIES TO THIS INVESTIGATIONAL INNOVATIVE THERAPEUTIC WITH A CLEAR POTENTIAL REGISTRATION PATH COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, NOVEMBER 13, 8:00 AM EASTERN TIME BRISBANE, CALIF., NOV. 13, 2025 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS, INC. (NASDAQ: DAWN) (DAY ONE OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED IT HAS SIGNED A DEFINITIVE MERGER AGREEMENT FOR DAY ONE TO ACQUIRE MERSANA THERAPEUTICS (MERSANA).

DAY ONE TO ACQUIRE MERSANA THERAPEUTICS TO ADVANCE MISSION TO BRING NEW MEDICINES TO PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES

THREE-YEAR FOLLOW-UP DATA FROM FIREFLY-1 DEMONSTRATES DURABLE RESPONSES WITH EVIDENCE OF CLINICAL STABILITY OFF TREATMENT, WITH THE POTENTIAL FOR RETREATMENT AFTER PROGRESSION TREATMENT-FREE INTERVAL DATA TO ALSO BE DISCLOSED FOR THE FIRST TIME BRISBANE, CALIF., NOV. 10, 2025 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS, INC. (NASDAQ: DAWN) (DAY ONE OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED IT WILL PRESENT NEW OJEMDA DURABILITY AND CLINICAL STABILITY DATA FROM THE REGISTRATIONAL FIREFLY-1 STUDY AT THE 30TH ANNUAL MEETING & EDUCATION DAY OF THE SOCIETY FOR NEURO-ONCOLOGY (SNO), BEING HELD NOVEMBER19-23, 2025.

DAY ONE ANNOUNCES NEW OJEMDA (TOVORAFENIB) DATA TO BE PRESENTED IN ORAL SESSION AT THE 2025 SOCIETY FOR NEURO-ONCOLOGY (SNO) ANNUAL MEETING

COMMERCIAL EXECUTION DELIVERS BEST QUARTER LAUNCH-TO-DATE WITH GROWTH ACROSS ALL DIMENSIONS OF CORE BUSINESS RAISING OJEMDA FULL-YEAR 2025 NET PRODUCT REVENUE GUIDANCE TO $145 TO $150 MILLION THREE-YEAR FIREFLY-1 DATA TO BE RELEASED IN ORAL PRESENTATION AT SOCIETY FOR NEURO-ONCOLOGY ON NOV. 23, 2025 ENDED THE THIRD QUARTER WITH $451.6 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, NOVEMBER 4, 4:30 P.M. EASTERN TIME BRISBANE, CALIF.

DAY ONE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND CORPORATE PROGRESS

BRISBANE, CALIF., OCT. 21, 2025 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS (NASDAQ: DAWN) (DAY ONE OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST ON TUESDAY, NOVEMBER 4, 2025 AT 4:30 P.M. ET TO REPORT FINANCIAL RESULTS AND DISCUSS CORPORATE PROGRESS FOR THE THIRD QUARTER 2025.

DAY ONE TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS TUESDAY, NOVEMBER 4, 2025

OJEMDA (TOVORAFENIB) NET PRODUCT REVENUE OF $33.6 MILLION IN Q2 2025, A 10% QUARTER-OVER-QUARTER INCREASE OJEMDA FULL-YEAR 2025 NET PRODUCT REVENUE EXPECTED TO BE $140 TO $150 MILLION ENDED THE SECOND QUARTER WITH $453.1 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, AUGUST 5, 4:30 P.M. ET BRISBANE, CALIF.

DAY ONE REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND CORPORATE PROGRESS

BRISBANE, CALIF., JULY 22, 2025 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS (NASDAQ: DAWN) (DAY ONE OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST ON TUESDAY, AUGUST 5, 2025 AT 4:30 P.M. ET TO REPORT FINANCIAL RESULTS AND DISCUSS CORPORATE PROGRESS FOR THE SECOND QUARTER 2025.

DAY ONE TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTSTUESDAY, AUGUST 5, 2025

DR. MICHAEL VASCONCELLES BRINGS MORE THAN 25 YEARS OF EXTENSIVE ONCOLOGY RESEARCH, DEVELOPMENT AND HEALTH TECHNOLOGY EXPERTISE AND CORPORATE EXECUTIVE LEADERSHIP TO DAY ONE

DAY ONE APPOINTS MICHAEL VASCONCELLES, M.D., ASHEAD OF RESEARCH AND DEVELOPMENT

OJEMDA (TOVORAFENIB) PRESCRIPTIONS GREW 16% IN Q1 2025 COMPARED TO Q4 2024 ACHIEVED Q1 2025 OJEMDA (TOVORAFENIB) NET PRODUCT REVENUE OF $30.5 MILLION ENDED THE FIRST QUARTER WITH $473.0 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, MAY 6, 4:30 P.M. ET BRISBANE, CALIF.

Day One Biopharmaceuticals, Inc.

DAWN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Day One Biopharmaceuticals, Inc.

DAWN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DAWN